Dual inhibition with anti-EGFR antibodies (cetuximab or pertuzumab) and anti-HER-2 antibody (tyrosine kinase inhibitor lapatinib) led in preclinical studies to a significant regression of the tumor (−75%) in comparison to treatment with cetuximab or lapatinib alone. This evidence concerns the gene ERBB2 and neoplasm.